axicabtagene ciloleucel,Cyclophosphamide,Fludarabine
gilead,daiichi sankyo
['axi-cel', 'alycante', 'lymphoma', 'lymsm']
congress|#eha2023 francois lemonnier presents results from the alycante trial investigating axi-cel as 2nd line therapy for treatment of lbcl. cmr at 3 months was 70% vs 12% expected with soc. or and cr rates were 92.5% and 80%, respectively #lymphoma #lymsm #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm